Alshammari, G.M.; Abdelhalim, M.A.; Al-Ayed, M.S.; Al-Harbi, L.N.; Yahya, M.A.
Concomitant Sub-Chronic Administration of Small-Size Gold Nanoparticles Aggravates Doxorubicin-Induced Liver Oxidative and Inflammatory Damage, Hyperlipidemia, and Hepatic Steatosis. Molecules 2023, 28, 796.
https://doi.org/10.3390/molecules28020796
AMA Style
Alshammari GM, Abdelhalim MA, Al-Ayed MS, Al-Harbi LN, Yahya MA.
Concomitant Sub-Chronic Administration of Small-Size Gold Nanoparticles Aggravates Doxorubicin-Induced Liver Oxidative and Inflammatory Damage, Hyperlipidemia, and Hepatic Steatosis. Molecules. 2023; 28(2):796.
https://doi.org/10.3390/molecules28020796
Chicago/Turabian Style
Alshammari, Ghedeir M., Mohamed Anwar Abdelhalim, Mohammed S. Al-Ayed, Laila Naif Al-Harbi, and Mohammed Abdo Yahya.
2023. "Concomitant Sub-Chronic Administration of Small-Size Gold Nanoparticles Aggravates Doxorubicin-Induced Liver Oxidative and Inflammatory Damage, Hyperlipidemia, and Hepatic Steatosis" Molecules 28, no. 2: 796.
https://doi.org/10.3390/molecules28020796
APA Style
Alshammari, G. M., Abdelhalim, M. A., Al-Ayed, M. S., Al-Harbi, L. N., & Yahya, M. A.
(2023). Concomitant Sub-Chronic Administration of Small-Size Gold Nanoparticles Aggravates Doxorubicin-Induced Liver Oxidative and Inflammatory Damage, Hyperlipidemia, and Hepatic Steatosis. Molecules, 28(2), 796.
https://doi.org/10.3390/molecules28020796
